India, Sept. 18 -- For Natera Inc. (NTRA), the journey so far has been nothing short of remarkable, with its shares scaling new heights to reach an all-time high of $366.70 yesterday.
Natera is a global provider of cell-free DNA (cfDNA) testing, with a focus on oncology, women's health and organ health. The company develops personalized genetic tests and diagnostics designed to support earlier detection, more targeted treatment decisions and improved patient outcomes.
The stock's ascent is not merely a matter of happenstance. Several factors have contributed to its remarkable run, including growing demand for Natera's products, continued momentum in its core business, and a series of upward revisions to its financial guidance.
When Did W...